Myelodysplastic syndrome (MDS) groups across Europe have come together to share ideas and findings. In this video, Valeria Santini, MD, University of Florence, Florence, Italy, discusses some of the MDS clinical trials currently underway in Europe, such as investigations in the use of lenalidomide in lower-risk patients with 5q(del), and studies evaluating the use of luspatercept in patients without ring sideroblasts. Prof. Santini goes on to talk on trials in higher-risk MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.